#United States #New York #Securities Class Action #Faruqi & Faruqi #Microvast

Attention Microvast Investors

Investors in Microvast Holdings, Inc. (NASDAQ: MVST) have a significant deadline approaching. Faruqi & Faruqi, LLP, a prominent securities law firm, is actively investigating claims related to the company's operations and is urging investors who suffered losses during a specific period to take action. This article aims to inform you about the ongoing class action lawsuit and how you can participate before the crucial deadline of September 21, 2026.

Overview of the Case

The investigation focuses on alleged violations of federal securities laws by Microvast and its executives. The firm's complaint claims that the company misled investors about its financial performance and operational capabilities. Key allegations include:

1. Overstated Profitability Targets: Microvast is accused of exaggerating its capacity to achieve desired profit margins, masking significant issues with inventory management and delays in vehicle rollouts.
2. Expansion Delays: The complaint points out that the company misrepresented the status of its Huzhou Phase 3.2 expansion project, stating it would be completed by late 2025 when it is now evident that operational capabilities were not ready until early 2026.
3. False Statements: Misleading public announcements and failure to disclose vital information have reportedly led to inflated stock prices and subsequent sharp declines following the truth's revelation.

Timeline of Events

The situation escalated dramatically over recent years, with key announcements sparking investor concern:

• - On June 25, 2025, allegations from short sellers suggested that Microvast was overstating activity within its facilities, causing a sharp drop in stock value.
• - Following the unexpected resignation of CFO Schultz on August 1, 2025, investors faced further losses, as the stock price sank nearly 10%.
• - The company's financial report on November 10, 2025, revealed production delays related to the Huzhou expansion, drastically impacting stock prices as investors reacted negatively to its incomplete promises.
• - By March 16, 2026, when Microvast revealed dire revenue results and an alarming margin decrease, the stock plummeted, causing investors to worry about their next steps.

Legal Considerations for Investors

Faruqi & Faruqi is offering help to those who acquired Microvast securities between April 1, 2025, and March 16, 2026. Investors can reach out to discuss their legal rights and possible claims arising from these alleged misrepresentations. To become a lead plaintiff – the person who will represent the group in court – potential participants must file a motion before the upcoming deadline.

How to Get Involved

If you have suffered losses on your Microvast investments during the defined class period, it is crucial to review your options swiftly. Here are some suggested steps:
1. Contact Legal Counsel: Reach out to Faruqi & Faruqi, LLP directly to evaluate your eligibility and discuss potential actions.
2. Understand Your Rights: Familiarize yourself with the class action process, including what it means to be a lead plaintiff and how that might impact your potential recovery.
3. Act Promptly: Given the deadline of September 21, 2026, time is of the essence.
4. Stay Informed: Monitor updates through the firm's communications and platforms for ongoing developments regarding the case.

Conclusion

The Microvast class action lawsuit represents not just a fight for financial recourse but a significant opportunity for investors to reclaim losses resulting from alleged securities fraud. With the expert guidance of firms like Faruqi & Faruqi, affected investors can pursue their legal rights effectively. Don't miss the crucial deadline – ensure that your voice and rights as an investor are duly represented. Reach out today for more assistance and take control of your financial future.

• ---

For additional information, you can visit www.faruqilaw.com/MVST or contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for a no-obligation consultation.